eISSN: 2084-9869
ISSN: 1233-9687
Polish Journal of Pathology
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

without publication fees
4/2024
vol. 75
 
Share:
Send email
Share:
Original paper

The impact of KRAS mutations on the tumour microenvironment and treatment response in non-small cell lung cancer

Guomin Gu
1
,
Chunling Liu
1
,
Yan Yang
1
,
Yan Zhao
1
,
Xiaodan Zhu
1
,
Gang Sun
1

  1. Department of Pulmonary Medicine, Affiliated Cancer Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China
Pol J Pathol 2024; 75 (4): 353-361
DOI: https://doi.org/10.5114/pjp.2024.146544
Online publish date: 2024/12/30
Article file
- The impact of KRAS.pdf  [1.41 MB]
Get citation
 
PlumX metrics:
 
1. Leiter A, Veluswamy RR, Wisnivesky JP. The global burden of lung cancer: current status and future trends. Nat Rev Clin Oncol 2023; 20: 624-639.
2. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin 2022; 72: 7-33.
3. Lahiri A, Maji A, Potdar PD, et al. Lung cancer immunotherapy: progress, pitfalls, and promises. Mol Cancer 2023; 22: 40. DOI: 10.1186/s12943-023-01740-y.
4. Yang H, Miao Y, Yu Z, et al. Cell adhesion molecules and immunotherapy in advanced non-small cell lung cancer: current process and potential application. Front Oncol 2023; 13: 1107631. DOI: 10.3389/fonc.2023.1107631.
5. Lau APY, Khavkine Binstock SS, Thu KL. CD47: the next frontier in immune checkpoint blockade for non-small cell lung cancer. Cancers (Basel) 2023; 15: 5229. DOI: 10.3390/cancers15215229.
6. Liu SM, Zheng MM, Pan Y, Liu SY, Li Y, Wu YL. Emerging evidence and treatment paradigm of non-small cell lung cancer. J Hematol Oncol. 2023;16:40; doi: 10.1186/s13045-023-01436-2.
7. Li MSC, Mok KKS, Mok TSK. Developments in targeted therapy & immunotherapy-how non-small cell lung cancer management will change in the next decade: a narrative review. Ann Transl Med 2023; 11: 358. DOI: 10.21037/atm-22-4444.
8. Garcia-Robledo JE, Rosell R, Ruiz-Patino A, et al. KRAS and MET in non-small-cell lung cancer: two of the new kids on the ‘drivers’ block. Ther Adv Respir Dis 2022; 16: 17534666211066064. DOI: 10.1177/17534666211066064.
9. Bontoux C, Hofman V, Brest P, et al. Daily practice assessment of KRAS status in NSCLC patients: a new challenge for the thoracic pathologist is right around the corner. Cancers (Basel) 2022; 14. DOI: 10.3390/cancers14071628.
10. Desage AL, Leonce C, Swalduz A, Ortiz-Cuaran S. Targeting KRAS mutant in non-small cell lung cancer: novel insights into therapeutic strategies. Front Oncol 2022; 12: 796832. DOI: 10.3389/fonc.2022.796832.
11. Otano I, Ucero AC, Zugazagoitia J, Paz-Ares L. At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC. Nat Rev Clin Oncol 2023; 20: 143-159. DOI: 10.1038/s41571-022-00718-x.
12. Moskalenko Y, Smorodska O, Deineka V, et al. Prognostic factors for recurrence in patients with surgically resected non-small cell lung cancer. Contemp Oncol (Pozn) 2022; 26: 239-246.
13. Mayakonda A, Lin DC, Assenov Y, et al. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res 2018; 28: 1747-1756.
14. Liu S, Wang Z, Zhu R, et al. Three differential expression analysis methods for RNA sequencing: limma, EdgeR, DESeq2. J Vis Exp 2021; 18. DOI: 10.3791/62528.
15. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005; 102: 15545-15550.
16. Wu T, Hu E, Xu S, et al. clusterProfiler 4.0: a universal enrichment tool for interpreting omics data. Innovation (Camb) 2021; 2: 100141. DOI: 10.1016/j.xinn.2021.100141.
17. Hanzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics 2013; 14: 7. DOI: 10.1186/1471-2105-14-7.
18. Yang W, Soares J, Greninger P, et al. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res 2013; 41: D955-D961. DOI: 10.1093/nar/gks1111.
19. Geeleher P, Cox N, Huang RS. pRRophetic: an R package for prediction of clinical chemotherapeutic response from tumor gene expression levels. PLoS One 2014; 9: e107468. DOI: 10.1371/journal.pone.0107468.
20. Cascetta P, Marinello A, Lazzari C, et al. KRAS in NSCLC: state of the art and future perspectives. Cancers (Basel) 2022; 14. DOI: 10.3390/cancers14215430.
21. Sunaga N, Miura Y, Kasahara N, Sakurai R. Targeting oncogenic KRAS in non-small-cell lung cancer. Cancers (Basel) 2021; 13. DOI: 10.3390/cancers13235956.
22. Ihle NT, Byers LA, Kim ES, et al. Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst 2012; 104: 228-239.
23. Ramalingam PS, Balakrishnan P, Rajendran S, et al. Identification of dietary bioflavonoids as potential inhibitors against KRAS G12D mutant-novel insights from computer-aided drug discovery. Curr Issues Mol Biol 2023; 45: 2136-2156.
24. Karimi N, Moghaddam SJ. KRAS-mutant lung cancer: targeting molecular and immunologic pathways, therapeutic advantages and restrictions. Cells 2023; 12. DOI: 10.3390/cells12050749.
25. Arbour KC, Rizvi H, Plodkowski AJ, et al. Treatment outcomes and clinical characteristics of patients with KRAS-G12C-mutant non-small cell lung cancer. Clin Cancer Res 2021; 27: 2209-2215.
26. Veluswamy R, Mack PC, Houldsworth J, et al. KRAS G12C-mutant non-small cell lung cancer: biology, develop­mental therapeutics, and molecular testing. J Mol Diagn 2021; 23: 507-520.
27. Liu C, Zheng S, Jin R, et al. The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity. Cancer Lett 2020; 470: 95-105.
28. Wang Z, Xing Y, Li B, et al. Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer. Mol Biomed 2022; 3: 42. DOI: 10.1186/s43556-022-00107-x.
29. Chmielewska I, Krawczyk P, Grenda A, et al. Breaking the ‘undruggable’ barrier: anti-PD-1/PD-L1 immunotherapy for non-small cell lung cancer patients with KRAS mutations – a comprehensive review and description of single site experience. Cancers (Basel) 2023; 15. DOI: 10.3390/cancers15143732.
30. Liu C, Zheng S, Wang Z, et al. KRAS-G12D mutation drives immune suppression and the primary resistance of anti-­PD-1/PD-L1 immunotherapy in non-small cell lung cancer. Cancer Commun (Lond) 2022; 42: 828-847.
31. Arbour KC, Rizvi H, Plodkowski AJ, et al. Treatment outcomes and clinical characteristics of patients with KRAS-G12C-mutant non-small cell lung cancer. Clin Cancer Res 2021; 27: 2209-2215.
32. Linh DM, Thinh TH, Hieu NV, Duc NM. Treatment outcomes of EGFR-TKI with or without locoregional brain therapy in advanced EGFR-mutant non-small cell lung cancer patients with brain metastases. Contemp Oncol (Pozn) 2023; 27: 71-79.
33. Sun Q, Hong Z, Zhang C, et al. Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends. Signal Transduct Target Ther 2023; 8: 320. DOI: 10.1038/s41392-023-01522-4.
34. Thommen DS, Schreiner J, Muller P, et al. Progression of lung cancer is associated with increased dysfunction of T cells defined by coexpression of multiple inhibitory receptors. Cancer Immunol Res 2015; 3: 1344-1355.
35. Tang S, Qin C, Hu H, et al. Immune checkpoint inhibitors in non-small cell lung cancer: progress, challenges, and prospects. Cells 2022; 11. DOI: 10.3390/cells11030320.
36. Dubovsky JA, Beckwith KA, Natarajan G, et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood 2013; 122: 2539-2549.
37. Yu W, Chen CZ, Peng Y, et al. KRAS affects adipogenic differentiation by regulating autophagy and MAPK activation in 3T3-L1 and C2C12 cells. Int J Mol Sci 2021; 22. DOI: 10.3390/ijms222413630.
38. Li JX, Li RZ, Ma LR, et al. Targeting mutant kirsten rat sarcoma viral oncogene homolog in non-small cell lung cancer: current difficulties, integrative treatments and future perspectives. Front Pharmacol 2022; 13: 875330. DOI: 10.3389/fphar.2022.875330.
39. O’Sullivan E, Keogh A, Henderson B, et al. Treatment strategies for KRAS-mutated non-small-cell lung cancer. Cancers (Basel) 2023; 15. DOI: 10.3390/cancers15061635.
Copyright: © 2024 Polish Association of Pathologists and the Polish Branch of the International Academy of Pathology This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2025 Termedia Sp. z o.o.
Developed by Bentus.